Drugs / PRX-105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01093859 | Mar → May 2010 | organophosphate poisoning | Protalix | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2011-11-10 | Protalix | Results Protalix's Acetylcholinesterase Demonstrates Potential Role in the Treatment of Parkinson's Disease protalix.com ↗
Furthermore, intravenous injection with PRX-105 induced a protective gene expression profile in the striatum of the brain. |
| 2010-06-08 | Protalix | Results Protalix BioTherapeutics Completes Phase I Clinical Trial for PRX-105 protalix.com ↗
Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today the completion of its phase I clinical trial of PRX-105, a plant cell expressed pegylated recombinant human acetylcholinesterase in development for biodefense indications. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-11-10 | Protalix | Protalix's Acetylcholinesterase Demonstrates Potential Role in the Treatment of Parkinson's Disease protalix.com ↗ |
| 2011-01-04 | Protalix | Protalix BioTherapeutics Announces Presentation of PRX-105 Data at the BARDA Industry Day protalix.com ↗ |
| 2010-06-08 | Protalix | Protalix BioTherapeutics Completes Phase I Clinical Trial for PRX-105 protalix.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRX-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01093859 ↗ |
| Route | Intravenous | “administered intravenously by slow bolus injection” NCT01093859 ↗ |